Strategic partnerships Aenitis recently announced a Memorandum of Understanding with Bracco Imaging, signaling potential for co-development or integration opportunities in contrast agent workflows, imaging centers, and contract research networks.

Clinical and industrial scale Their flagship Mitis platform enables scalable, gentle, contact-free cell handling across research, clinical, and industrial settings, suggesting sales opportunities in biomanufacturing, cell therapy production, and GMP-compliant processes.

Funding and credibility European Commission support, French government backing, and investors like EIB and Seventure Partners enhance credibility and may facilitate introductions to European biopharma customers and grant-backed pilots.

Proof-of-concept traction Proof-of-concepts across multiple cell types and processes indicate readiness for collaboration with pharma/biotech companies seeking novel sorting, isolation, concentration, and washing capabilities.

Market positioning Focus on acoustofluidic, millifluidic-scale, sterile, and label-free cell manipulation positions Aenitis to target niche mid-to-large-scale manufacturing players seeking safer, cheaper, and scalable cell/gene therapy workflows.